NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
0.9827
-0.0773 (-7.29%)
Apr 10, 2026, 4:00 PM EDT - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,188,349
Market Cap
21.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Jasper Therapeutics | 27 |
| Curis | 24 |
| Tevogen Bio Holdings | 18 |
| Quantum BioPharma | 17 |
| Lantern Pharma | 16 |
| Barinthus Biotherapeutics | 14 |
| VYNE Therapeutics | 10 |
NNVC News
- 4 days ago - Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - Accesswire
- 10 days ago - Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - Accesswire
- 4 weeks ago - NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - Accesswire
- 2 months ago - MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 2 months ago - Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 2 months ago - NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - Accesswire
- 3 months ago - NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 - Accesswire
- 4 months ago - NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Accesswire